Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2019 - 2025)
Historic Gains from Sales and Divestitures for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $75500.0.
- Protagonist Therapeutics' Gains from Sales and Divestitures changed N/A to $75500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75500.0, marking a year-over-year change of. This contributed to the annual value of $316748.0 for FY2024, which is 468.17% up from last year.
- Latest data reveals that Protagonist Therapeutics reported Gains from Sales and Divestitures of $75500.0 as of Q3 2025.
- Protagonist Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $316748.0 during Q4 2024, with a 5-year trough of $75500.0 in Q3 2025.
- In the last 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures had a median value of $104712.0 in 2022 and averaged $147548.4.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 4039.89% in 2021, then surged by 17152.67% in 2023.
- Over the past 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $78165.0 in 2021, then soared by 38.76% to $108462.0 in 2022, then skyrocketed by 178.98% to $302582.0 in 2023, then grew by 4.68% to $316748.0 in 2024, then crashed by 76.16% to $75500.0 in 2025.
- Its Gains from Sales and Divestitures was $75500.0 in Q3 2025, compared to $316748.0 in Q4 2024 and $302582.0 in Q4 2023.